T-SPOT.TBresponses during treatment of pulmonary tuberculosis
Open Access
- 28 February 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 9 (1), 23
- https://doi.org/10.1186/1471-2334-9-23
Abstract
Immune responses to Mycobacterium tuberculosis antigens could serve as surrogate markers of treatment response. Using the T-SPOT.TB assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB patients receiving directly observed treatment. T cell responses (measured as "spot forming cells" or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment. 58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of 24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6, CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20), and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were higher than those without cavitary disease (IRR 2.08, p = 0.034). IFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.TB assay, may be directly related to bacterial load in patients undergoing treatment for pulmonary TB. However, high inter-subject variability in quantitative results coupled with failure of reversion to negative of qualitative results in most subjects at treatment completion may limit the utility of this assay as a surrogate marker for treatment efficacy.Keywords
This publication has 28 references indexed in Scilit:
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Diagnosis of Tuberculosis by an Enzyme-Linked Immunospot Assay for Interferon-γEmerging Infectious Diseases, 2007
- T-Cell–Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis InfectionPublished by American Academy of Pediatrics (AAP) ,2007
- Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN- Assay for the Diagnosis of Mycobacterium tuberculosis InfectionClinical Medicine & Research, 2006
- Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot studyClinical Microbiology & Infection, 2006
- Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cellsLeukemia, 2005
- Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practiceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Quantitative T Cell Assay Reflects Infectious Load of Mycobacterium tuberculosis in an Endemic Case Contact ModelClinical Infectious Diseases, 2005
- Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantationLeukemia, 2004
- Depressed T‐Cell Interferon‐γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with TherapyThe Journal of Infectious Diseases, 1999